Gilead

medicine

Remdesivir Medicine Market Will Hit Big Revenues In Future | Sanofi, Gilead Sciences, GlaxoSmithKline – Press Release

Remdesivir Medicine Market Will Hit Big Revenues In Future | Sanofi, Gilead Sciences, GlaxoSmithKline

Remdesivir Medicine Comprehensive Study by Application (Ebola Virus Disease, Marburg Virus Infection, Possible COVID-19 Treatment), Administration (Oral, Intravenous), End-users (Hospitals, Clinics, Ambulatory Surgical Centers, Others), Distribution Channel (Online Channel, Offline Channel) Players and Region – Global Market Outlook to 2025.

Global Remdesivir Medicine Market Comprehensive Study is an expert and top to bottom investigation on the momentum condition of the worldwide Global Remdesivir Medicine industry with an attention on the Global market. The report gives key insights available status of the Global Remdesivir Medicine producers and is an important wellspring of direction and course for organizations and people keen on the business. By and large, the report gives an inside and out understanding of 2020-2025 worldwide Remdesivir Medicine Market covering extremely significant parameters.

Key Players in This Report Include,
Gilead Sciences, Inc. (United States), Hainan Haiyao Co., Ltd. (China), Sanofi S.A. (France), GlaxoSmithKline plc (United Kingdom) and Cipla (India)

Free Sample Report + All Related Graphs & Charts @: https://www.advancemarketanalytics.com/sample-report/128698-global-remdesivir-medicine-market

Brief Summary of Global Remdesivir Medicine:
Remdesivir medicine is an anti-viral medication being studied as a possible post-infection treatment for COVID-19 illness. This medicine is a nucleotide analog, specifically an adenosine analog, which inserts into viral RNA chains causing their premature termination. It was developed by Gilead Sciences as a treatment for Ebola virus disease and Marburg virus infections. It is an investigational antiviral compound undergoing clinical trials in China, the United States and the United Kingdom as a potential treatment for COVID-19. It is not yet licensed or approved anywhere globally and has not been demonstrated to be safe or effective for any use.

Market Drivers

  • Increased Prevalence of COVID-19 Illness
  • Highly Effective Anti-viral Medicine

 

Market Trend

  • High Demand for Coronavirus Disease Treatment

 

Restraints

  • Lack of Clinical Evidence for COVID-19 Treatment

 

Opportunities

  • Increasing Number of Patients affecting COVID-19
  • Growth in the Healthcare Industry

 

Challenges

  • Stringent Government Rules and Regulations

This research report represents a 360-degree overview of the competitive landscape of the Global Remdesivir Medicine Market. Furthermore, it offers massive data relating to recent trends, technological, advancements, tools, and methodologies. The research report analyzes the Global Remdesivir Medicine Market in a detailed and concise manner for better insights into the businesses.

Regions Covered in the Global Remdesivir Medicine Market:

  • The Middle East and Africa (South Africa, Saudi Arabia, UAE, Israel, Egypt, etc.)
  • North America (United States, Mexico & Canada)
  • South America (Brazil, Venezuela, Argentina, Ecuador, Peru, Colombia, etc.)
  • Europe (Turkey, Spain, Turkey, Netherlands Denmark, Belgium, Switzerland, Germany, Russia UK, Italy, France, etc.)
  • Asia-Pacific (Taiwan, Hong Kong, Singapore, Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia).


Enquire for customization in Report @ https://www.advancemarketanalytics.com/enquiry-before-buy/128698-global-remdesivir-medicine-market

The research study has taken the help of graphical presentation techniques such as infographics, charts, tables, and pictures. It provides guidelines for both established players and new entrants in the Global Remdesivir Medicine Market.

The detailed elaboration of the Global Remdesivir Medicine Market has been provided by applying industry analysis techniques such

Read More
health

Gilead questions WHO study that cast doubts on drug’s COVID-19 benefits

By Deena Beasley and Vishwadha Chander

(Reuters) – Gilead Sciences Inc has questioned the findings of a World Health Organization (WHO) study that concluded its COVID-19 drug remdesivir does not help patients who have been admitted to hospital.

The American company told Reuters the data appeared inconsistent, the findings were premature and that other studies had validated the drug’s benefits.

In a blow to one of the few drugs being used to treat people with COVID-19, the WHO said on Thursday its “Solidarity” trial had concluded that remdesivir appeared to have little or no effect on 28-day mortality or length of hospital stays among patients with the respiratory disease.

The antiviral medication was one of the drugs used to treat U.S. President Donald Trump’s coronavirus infection, and has been shown in previous studies to have cut time to recovery, though the European Union is investigating it for possible kidney injury.

The WHO trial was conducted in 11,266 adult patients in more than 30 countries. The evidence was conclusive, the WHO said.

Gilead said other trials of remdesivir, including with 1,062 patients that compared it with a placebo, showed the treatment cut COVID-19 recovery time.

“The emerging (WHO) data appears inconsistent, with more robust evidence from multiple randomized, controlled studies published in peer-reviewed journals validating the clinical benefit of remdesivir,” Gilead told Reuters.

Gilead said it was “unclear if any conclusive findings can be drawn” given what it called differences in how the trial was conducted from site to site and between the patients who received the medicine.

In April, the top U.S. infectious disease official, Anthony Fauci, predicted remdesivir would become “the standard of care”.

Companies such as Gilead are racing to find a treatment for COVID-19. Some 1.1 million people have died and 39.1 million have been reported infected in the pandemic, and the global economy has been thrown into chaos.

Remdesivir was developed for Ebola, which causes fever, bleeding, vomiting and diarrhoea and spreads among humans through bodily fluids.

It was quickly repurposed and has offered some hope for patients, though the WHO’s findings may shift the focus of the search for a vaccine to new monoclonal antibodies being developed by companies including Regeneron.

The Solidarity trial also evaluated hydroxychloroquine, anti-HIV drug combination lopinavir/ritonavir and interferon, and concluded that they, like remdesivir, did little to help patients survive or leave the hospital more quickly.

The WHO trial’s results are yet to be reviewed and were uploaded on the preprint server medRxiv. (https://bit.ly/3nViYIf)

“PREMATURE”

Gilead say the Solidarity conclusions, lacking scrutiny from other scientists, were premature.

“We are concerned the data from this open-label global trial has not undergone the rigorous review required to allow for constructive scientific discussion, particularly given the limitations of the trial design,” it said.

Remdesivir got emergency use authorization from the U.S. Food and Drug Administration on May 1, and has been authorized for use in several countries.

During the Solidarity study, trials of hydroxychloroquine and lopinavir/ritonavir were stopped in June after

Read More